Evidence map›Paper›PMID 35707623›Full record

ArticleTH open : companion journal to thrombosis and haemostasis2022

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study.

Carmen Escuriola Ettingshausen, Vladimír Vdovin, Nadezhda Zozulya, Pavel Svirin, Tatiana Andreeva, Majda Benedik-Dolničar, Victor Jiménez-Yuste, Lidija Kitanovski, Silva Zupancic-Šalek, Anna Pavlova and 10 more

Abstract read
In one paragraph

Article in TH open : companion journal to thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Carmen Escuriola EttingshausenHZRM, Hämophilie-Zentrum Rhein Main, Mörfelden-Walldorf, Germany.
Vladimír VdovinMorozovskaya Children's Hospital, Moscow, Russian Federation.
Nadezhda ZozulyaNational Research Center for Hematology, Moscow, Russian Federation.
Pavel SvirinMorozovskaya Children's Hospital, Moscow, Russian Federation.
Tatiana AndreevaCity Center for the Treatment of Hemophilia Patients, City Polyclinic N° 37, St. Petersburg, Russian Federation.
Majda Benedik-DolničarChildren's Hospital Oncology-Hematology Unit, University Medical Center Ljubljana, Ljubljana, Slovenia.
Victor Jiménez-YusteServicio de Hematología, Hospital Univeristario La Paz, Autónoma University, Madrid, Spain.
Lidija KitanovskiChildren's Hospital Oncology-Hematology Unit, University Medical Center Ljubljana, Ljubljana, Slovenia.
Silva Zupancic-ŠalekDivision of Haematology, Haemophilia Centre, University Hospital REBRO, Zagreb, Croatia.
Anna PavlovaInstitute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
Angelika BátorováDepartment of Hematology and Transfusion Medicine, National Hemophilia Center, Faculty of Medicine of the Comenius University and University Hospital, Bratislava, Slovak Republic.
Cesar Montaño MejíaHemolife and Universidad Tecnológica de Pereira, Pereira, Colombia.
Gulnara AbdilovaScientific Center of Pediatrics and Pediatric Surgery, Almaty, Kazakhstan.
Sigurd KnaubOctapharma AG, Lachen, Switzerland.
Martina JansenOctapharma Pharmazeutika Produktionsges.mbH, Vienna, Austria.
Shannely LowndesOctapharma AG, Lachen, Switzerland.
Larisa BelyanskayaOctapharma AG, Lachen, Switzerland.
Olaf WalterOctapharma AG, Lachen, Switzerland.
Johannes OldenburgInstitute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
ObsITI Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

factor VIIIFVIII inhibitorshemophilia Aimmune tolerancevon Willebrand factor

Identifiers

PMID35707623
PMCPMC9135478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.